Tenax Therapeutics (TENX) EBITDA (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly EBITDA of -$18.8 million for Q2 2026, down 59.29% year-over-year from -$46.1 million in Q2 2025, and down 13.34% on a QoQ basis from -$16.6 million in Q1 2026.
Tenax Therapeutics (TENX) EBITDA (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported EBITDA for 16 years, with the latest figure at -$18.8 million in Q2 2026.
- EBITDA for Q2 2026 came in at -$18.8 million, down 59.29% year-over-year; the trailing twelve-month figure through Jun 2026 was -$68.6 million (down 95.79% YoY), and the FY2025 annual result was -$56.4 million, down 189.24% from the prior year.
- EBITDA declined to -$18.8 million in Q2 2026, from -$16.6 million in the prior quarter.
- Over five years, EBITDA peaked at $2.9 million in Q3 2022 and troughed at -$18.8 million in Q2 2026.
- A 5-year average of -$6.2 million and a median of -$4.3 million in 2024 frame the typical range for EBITDA.
- The widest annual swing landed in 2022, when EBITDA jumped 104.1%; it then sank 613.85% in 2023.
- A 5-year view of EBITDA shows it stood at $2.6 million in 2022, then sank by 613.85% to -$13.1 million in 2023, then jumped by 44.43% to -$7.3 million in 2024, then tumbled by 125.48% to -$16.4 million in 2025, then declined by 14.2% to -$18.8 million in 2026.
- Per Business Quant data, the three most recent EBITDA figures were -$18.8 million in Q2 2026, -$16.6 million in Q1 2026, and -$16.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Tenax Therapeutics | 80.73 Mn | 80.73 Mn | - | -18.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.78 Mn |
| Mar 31, 2026 | -16.57 Mn |
| Dec 31, 2025 | -16.45 Mn |
| Sep 30, 2025 | -16.81 Mn |
| Jun 30, 2025 | -11.79 Mn |
| Mar 31, 2025 | -11.34 Mn |
| Dec 31, 2024 | -7.30 Mn |
| Sep 30, 2024 | -4.62 Mn |
| Jun 30, 2024 | -3.67 Mn |
| Mar 31, 2024 | -3.91 Mn |
| Dec 31, 2023 | -13.13 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | -1.54 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 2.72 Mn |
| Dec 31, 2021 | -62.24 Mn |
| Sep 30, 2021 | 3.80 Mn |